Most of their generic pharma sales are overseas. They do some otc stuff that may see the US markets, but you won’t get generic augmentin from them here. They have a good niche. Probably less regulations to deal with when focusing on South America, Africa, etc. also, I’m not sure of what their manufacturing capacity is, which would be nice to know.
All in all, and I’ve had my moments of pure hatred for this company, but that last PR with a seasoned pro now at the helm is screaming ‘all systems go’ for me.
I think there was a decent company hiding under Shah’s profound incompetence...now we get to see it.
Prediction: we break .01 by end of year, maybe even hold that level.
News 
Market Data 
Discover 
